In the treatment of gastroesophageal reflux disease (GERD), Risk reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer, Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+ /K+ -ATPase in the gastric parietal cell.
In Gastroesophageal Reflux Disease (GERD) (20 mg or 40 mg): One tablet daily for 4 to 8 weeks. In NSAID - Associated Gastric Ulcer (20 mg or 40 mg): Once daily for up to 6 months. In H. pylori Eradication (Triple Therapy) (40 mg): Once daily for 10 days.
Hypersensitivity to any of the ingredients/components of the product.
Therapy with esomeprazole does not preclude the presence of gastric malignancy. Avoid concomitant use of esomeprazole/omeprazole with clopidogrel. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea. Atrophic gastritis has been noted with long-term omeprazole therapy. Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.
Pregnancy: Pregnancy Category C. Esomeprazole is likely present in human milk. Caution should be exercised when administered to a nursing woman. Safety and effectiveness of esomeprazole have not been established in patients less than 1 month of age.
Esomeprazole may affect plasma levels of antiretroviral drugs – use with atazanavir and nelfinavir is not recommended. Esomeprazole interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin and mycophenolate mofetil).
The most common adverse effects are headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS